As for being a home run or not. We know that Leronlimab
As for being a home run or not. We know that Leronlimab works and when and how much in dose size and how often are all things the doctors can justify and prescribe as we go forward once we have a BLA. We just need to show that we work to get a EUA. If we continue to just trial for each different Covid-19 level of disease. It will be a while before we see wide spread use. Who knows... maybe we work best if we dose at Moderate and half the normal rate of SOC/placebo patients continue to Severe and then we dose again and half of those patients don’t go to critical. Then we continue to dose the critical one dose every day until nobody dies. These are possibilities for doctors to try and not left up to trials when we get a BLA. It’s far to slow to continue trials for every covid indication and to many people will die before we get through all the trials possible we can think up for dosing and length of time between.
Good doctors will figure this all out by lab results and being attentive to their occupation as doctors. If our safety continues its golden path and is what we believe it will be going forward. Then Leronlimab could work excellent for Covid. Trials won’t necessarily show all the potential we hope to see. But use in the pandemic will be written about in journals and advertised or spoken about in presentations or even word of mouth social media throughout the medical field.
We just need to get over the hump on the first trial EUA approved before we learn just what Leronlimab can actually do during this early stages of this pandemic. For this, I am excited to see the potential. We are not limited overall by only one or two early trial results. It’s just the beginning of use is all. The door will be opened for more extensive use when we get BLA approval. Then we will all figure out just how good Leronlimab is. This is what I hope will shine through for us all. A drug that works and saves lives. How it is administered or how often we dose it, should be left up to the professionals. Safety will dictate the use of Leronlimab. Let’s hope our safety record holds true. This is the most important aspect going forward as an investor or a patient. As safety allows more of a universal common sense use and ability to change doses and time between doses as doctors dial in the proper use of any drug.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Baijiu Brews Cultural Ties at Melbourne Cup If you thought the Melbourne Cup was only about horse racing, think again. This year, the carnival wasn’t just a playground for the equestrian elite but also a stage for cultural exchange, and Chinese baijiu had its moment to shine. It’s not just about sipping a strong spirit; it's about bridging cultures and building...
Continue Reading
Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...
Continue Reading
HONOR X9e Pro: Built for the Game Lover You're out there on the court, hitting balls or shooting goals, and the last thing you want is your phone gasping for power halfway through the day. The HONOR X9e Pro swoops in like the hero of your weekend hangouts, designed to handle everything from impromptu matches to capturing those unforgettable winning moments. We're not just...
Continue Reading
Where Fragrance Meets Innovation Ever wondered how the wafting elegance of a perfume bottle finds its way from a mere idea to the shelf? At Cosmoprof Asia 2026 in Hong Kong, Xuelei has laid it all bare with their triple treat showcase. Picture this: you stroll through a vast array of what seems like an olfactory wonderland, where one can pluck the essence of fine...
Continue Reading
Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....
Continue Reading
Cracks in the Foundation: CVRx's Turmoil Let me tell you, it's not every day you see a company drop a bombshell on investors like CVRx did, shaking up the ole portfolio right down to its socks. NASDAQ:CVRX has found itself embroiled in a class action lawsuit courtesy of a knotty mix of legal woes, unplanned revenue slashes, and executive shake-ups. A few short years ago,...
Continue Reading
Fresh Bonds Meet Digital Rails In the ever-changing landscape of institutional finance, innovation comes wrapped in unexpected packages, and this time it's got a digital bow on it. Membrane Labs and M1X Global recently announced the integration of USDM1, a snazzy USD-denominated sovereign bond, right into Membrane's established institutional credit and lending...
Continue Reading
Beyond the Hype: Innovating for Healthier Tomorrows Kicking off in Stockholm on December 1st, the 2026 Prix Galien Bridges Awards isn't just some schmooze-fest; it's a hard-hitting showcase of where true innovation can propel healthcare. Over at the Karolinska Institutet, the Galien Foundation is drawing powerhouses from across the Nordics+ region and showcasing...
Continue Reading
Leadership Takes an Unexpected Turn at Capital Properties When the helm of a ship faces turbulence, everyone's eyes turn to the captain. In the case of Capital Properties, Inc., their captain, Chairman, CEO and President Robert H. Eder, has hit a personal snag, diagnosed with cancer but determined to steer steady despite the storm brewing within. A Glance at Capital...
Continue Reading
PU200's Debut: Making Safety and Space Work in Tandem Ever noticed how safety's become the name of the game for data center operations? Powered by the influx of AI, these digital fortresses crave robust power backup, and Ampace’s stepping in with their PU200 UPS battery solution at Data Centre World Paris 2026. Showing off at Hall 5, Booth M65, Ampace's bringing to the...
Continue Reading
Top 5 Most Recently Viewed Articles
American Financial Group Reports Fourth Quarter Results American Financial Group, Inc. (NYSE: AFG) recently shared its financial highlights for the fourth quarter and the full year of 2024. The company reported fourth quarter net earnings of $255 million, which translates to $3.03 per share. This indicates a slight decrease compared to the $263 million ($3.13 per share)...
Continue Reading
Exciting Times for Mutuum Finance (MUTM) as V1 Launch Approaches As the decentralized finance (DeFi) market continues to evolve, one project that is capturing considerable attention is Mutuum Finance (MUTM). This innovative platform is gearing up for the launch of its V1 protocol on the Sepolia Testnet, a significant step scheduled for Q4 2025. Strong Investor Interest...
Continue Reading
Rockpoint Purchases The Morgan Provost Square Rockpoint, a well-known real estate private equity firm based in Boston, has announced an exciting new addition to its property portfolio. This acquisition involves The Morgan Provost Square, a vibrant Class A apartment community known for its luxurious living spaces and prime location. The precise financial terms of this deal...
Continue Reading
Acknowledgment of Casey L. Heer GRANDBY, Colo. – Prominently featured in The Inner Circle, Casey L. Heer is recognized as a Pinnacle Professional Member Inner Circle of Excellence for his exceptional contributions in water marine insurance. Casey Heer: A Leader in the Industry Casey L. Heer, President of Casey Insurance Group, is a distinguished figure in the realm of...
Continue Reading
Accor's Expansion in the Luxury Hospitality Market Accor, a prominent name in the hospitality industry, is making strides in luxury accommodations with new hotel projects. This latest venture involves a partnership with Dangayach Group aimed at developing two exquisite hotels in a sought-after destination. The hotels, Raffles Goa Shiroda and Fairmont Goa Shiroda, will be...
Continue Reading
